Published in

Cell Press, Cancer Cell, 7(39), p. 989-998.e5, 2021

DOI: 10.1016/j.ccell.2021.05.009

Links

Tools

Export citation

Search in Google Scholar

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

Journal article published in 2021 by Lajos Pusztai, Christina Yau ORCID, Denise M. Wolf, Hyo S. Han, Lili Du, Anne M. Wallace, Erica String-Reasor ORCID, Judy C. Boughey, A. Jo Chien, Anthony D. Elias, Heather Beckwith ORCID, Rita Nanda, Kathy S. Albain, Amy S. Clark, Kathleen Kemmer and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO